[类风湿性关节炎:2026年口服葡萄皮质类药物将发挥什么作用?]
Paul Cuenot1, Alexandre Dumusc1
1Service de rhumatologie, Département de l'appareil locomoteur, Centre hospitalier universitaire vaudois,, 1010 Lausanne.
Revue medicale suisse
|March 11, 2026
概括
口服葡萄皮质类药物 (OGCs) 有效地治疗类风湿性关节炎 (RA),但会带来诸如心血管疾病和骨质疏松症等风险. 长期使用OGC是不建议的,因为副作用和依赖性,有更安全的替代品可用.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 75多年来,口服葡萄糖皮质类药物 (OGC) 是类风湿性关节炎 (RA) 治疗的基石.
- 转基因药物在减少疾病活性和减缓RA患者放射性进展方面表现出有效性.
- 然而,OGC与包括心血管疾病和骨质疏松症在内的显著不良事件有关,特别是在长时间使用和更高剂量的情况下.
研究的目的:
- 审查与口服葡萄糖皮质体在类风湿性关节炎中使用相关的确定的益处和重大风险.
- 评估当前关于短期使用OGC与其他RA疗法结合使用的建议和正在进行的辩论.
- 突出OGCs停止的挑战和替代治疗方法的可用性.
主要方法:
- 对治疗类风湿性关节炎时口服葡萄糖皮质类药物研究的文献综述.
- 对有效性,安全性概况和长期结果的数据分析.
- 检查临床实践指南和研究OGC逐渐缩小和替代疗法.
主要成果:
- 机体脂肪酸可以快速缓解症状,但会增加感染的风险,即使是低剂量.
- 长期的OGC治疗不建议,因为相关的并发症,如心血管疾病和骨质疏松症.
- 其他治疗方法,包括免疫抑制剂和生物药物,在6个月内显示出与OGCs相似的疗效.
- 很大一部分患者 (30-50%) 即使经过两年的治疗,也难以停止使用OGC.
结论:
- 虽然OGCs为RA提供短期益处,但长期使用与不可接受的风险有关.
- 快速疗效的潜力必须与增加的感染风险和长期不良影响相对衡量.
- 有效的缓解策略和促进替代性RA疗法对于管理类风湿性关节炎和最大限度地减少与葡萄糖皮质激素相关的危害至关重要.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
01:29Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884
01:20The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692